Sponsored content – Interview Needham
and reduction in the use of solvents. The convenience of these types of devices will allow their use at bio- analytical laboratories and on a larger scale to clinical laboratories all around the world. What I observed this year at many key conferences,
AAPS, CPSA, etc., is that the day has arrived of us understanding that our role as a bioanalytical chemist is to deliver data to help in the decision making of a patient in consultation with their healthcare provider. The more tools and data we can provide directly to the patient, the better health outcomes the patient will afford. The discussions in the industry and at key conferences are starting to focus on the patient – and this is exactly what we want for the best patient outcomes.
Q What do you think is the greatest technological obstacle faced by bioanalysts
today? I think the greatest technological obstacle faced by bioanalysts today is remembering that we should focus on the patient. To do this we need to be help- ing develop point-of-care devices. With LC-MS/MS as the gold standard in instrumentation, we need to think outside the box and develop smaller, more cost-effective instruments that are more convenient to patient use at home. The instruments need to be for targeted assays for disease maintenance. These devices exist for many forms of disease (diabetes, bipolar disorder, etc.) and now we need to develop a versatile instrument for many different types of targeted biomarkers and therapeutics.
Looking to the future
Q What are you excited about working on in 2016? I am really excited for the expansion of our laboratory that includes GC-MS/MS bioanalysis. It appears that so many projects not LC-MS amenable were put ‘on- hold’ by our sponsors and now that regulated GC-MS/ MS is available, the need for assays is vast. Small bio- markers, hormone entities, semi-volatile small metabo- lites, fatty acids, cleavage products and potentially small toxic metabolites are all projects that are lined-up for our GC-MS/MS instrumentation.
Q What new technology would you like to see in the future, & how would this improve your work?
Alturas Analytics will continue to be involved in the development of microflow LC-MS and integrated sources for bioanalysis. We are also in discussions with researchers on the development of point-of-care devices and applications for use in bioanalysis. This collabora- tion with our vendors, academia and our sponsors will be exciting to watch develop as we continue to create new tools for the improvement of bioanalysis to facili- tate better patient outcomes.
Financial & competing interests disclosure The authors have no relevant affiliations or financial involve- ment with any organization or entity with a financial inter- est in or financial conflict with the subject matter or mate- rials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this
manuscript.
Bioanalysis (2016)
future science group
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154